BIOSECURE Act of 2025
Sponsored By: Senator Gary Peters
Introduced
Summary
Restricts federal contracting with identified "biotechnology companies of concern" by blocking agencies from buying certain biotech equipment or services and setting up a federal process to list, review, and waive those firms.
Show full summary
- Federal agencies would be barred from procuring or contracting for biotechnology equipment or services produced by listed companies and from using loan or grant funds to obtain those products.
- Companies and their parents, subsidiaries, or successors could be placed on a DoD-informed list, get a designation notice, have 90 days to oppose, and face phased prohibitions that start 60 or 90 days after Federal Acquisition Regulation updates.
- The Office of Management and Budget could grant case-by-case waivers with 30-day congressional notice, generally up to 365 days with one possible 180-day national-security extension; the bill also carves out exceptions for certain intelligence activities, overseas U.S. health care, public multiomic data, and public health emergency countermeasures.
*The bill does not authorize additional funds to carry out its provisions.*
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
6 provisions identified: 2 benefits, 3 costs, 1 mixed.
Risk study and annual intelligence reports
If enacted, the Director of National Intelligence would assess national-security risks from foreign-held U.S. human multiomic data and finish the study within 270 days. The DNI must send an unclassified report to Congress within 30 days after completing the assessment, with an optional classified annex. The DNI would also report to Congress within 180 days of enactment and then every year on intelligence about nefarious activity by biotech firms holding multiomic data and threats from transfers to foreign countries.
How the government names risky firms
If enacted, the Office of Management and Budget would publish a federal list of biotechnology companies of concern within one year. OMB would base the list in part on a DoD-provided list and coordinate with other agencies. Companies designated under the non-DoD criteria must get notice, have 90 days to oppose, and may be told possible mitigation steps. OMB must review the list at least once a year and reply to removal requests within 90 days.
Ban on federal biotech purchases
If enacted, federal agencies would be barred from buying biotech equipment or services made by designated companies. The bill would define covered items broadly, including sequencers, parts, and the software needed to run them. It would also define which firms are "biotechnology companies of concern," including DoD-listed firms and firms tied to foreign adversaries, plus parents and subsidiaries. The ban would cover contracts, grants, and loans and take effect 60 days after FAR changes for Defense-listed firms and 90 days for other listed firms.
VA deemed compliant for Medicaid pricing
If enacted, certain drug manufacturers would be treated as meeting VA master agreement rules for Medicaid price calculations when the procurement ban prevents formal VA agreements. The VA Secretary must determine the manufacturer would have complied but for the ban. This could help keep Medicaid drug pricing calculations stable for beneficiaries.
No new money for implementation
If enacted, the bill would not authorize any new funds to carry out these rules. Agencies would have to use existing budgets, which could slow or limit how quickly parts of the program are put in place.
Agency waivers and procurement exceptions
If enacted, the bill would create narrow exceptions and waivers allowing some purchases despite the ban. Exceptions include authorized intelligence work, lawfully compiled public or commercial multiomic data, medical countermeasures during a declared public health emergency, and certain overseas health care for U.S. personnel. Agencies could also grant case-by-case waivers (usually up to 365 days) with OMB approval and must notify Congress. OMB would issue implementation guidance and the FAR would be updated so contractors and buyers know the new rules.
Sponsors & CoSponsors
Sponsor
Gary Peters
MI • D
Cosponsors
Bill Hagerty
TN • R
Sponsored 12/11/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in